Evidence map›Paper›PMID 37709325›Full record

ArticleBMJ open2023

Estimating the cost impact of atrial fibrillation using a prospective cohort study and population-based controls.

Helena Aebersold, Fabienne Foster-Witassek, Miquel Serra-Burriel, Beat Brüngger, Stefanie Aeschbacher, Jürg-Hans Beer, Eva Blozik, Manuel Blum, Leo Bonati, David Conen and 16 more

Abstract read
In one paragraph

Article in BMJ open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Evolution in electrophysiology 100 years after Einthoven: translational and computational innovations in rhythm control of atrial fibrillation.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Helena AebersoldEpidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland helena.aebersold@uzh.ch.ORCID 0000-0002-4418-9904
Fabienne Foster-WitassekEpidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland.
Miquel Serra-BurrielEpidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland.
Beat BrünggerDepartment of Health Sciences, Helsana Group, Zurich, Switzerland.ORCID 0000-0001-6173-5375
Stefanie AeschbacherDepartment of Medicine, Cardiology Division, University Hospital Basel, Basel, Switzerland.
Jürg-Hans BeerDepartment of Medicine, Baden Cantonal Hospital, Baden, Switzerland.
Eva BlozikInstitute of Primary Care, University of Zurich, Zurich, Switzerland.
Manuel BlumInstitute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland.
Leo BonatiDepartment of Neurology, University Hospital Basel, Basel, Switzerland.
David ConenPopulation Health Research Institute, McMaster University, Hamilton, Ontario, Canada.
Giulio ConteDivision of Cardiology, Cardiocentro Ticino (CCT), Lugano, Switzerland.
Stefan FelderFaculty of Business and Economics, University of Basel, Basel, Switzerland.
Carola HuberDepartment of Health Sciences, Helsana Group, Zurich, Switzerland.ORCID 0000-0002-2469-0435
Michael KuehneDepartment of Medicine, Cardiology Division, University Hospital Basel, Basel, Switzerland.
Giorgio MoschovitisDivision of Cardiology, Ente Ospedaliero Cantonale (EOC), Instituto Cardiocentro Ticino, Ospedale Regionale di Lugano, Lugano, Switzerland.ORCID 0000-0002-4043-8061
Andreas MuellerDepartment of Cardiology, Triemli Hospital Zurich, Zurich, Switzerland.
Rebecca E PaladiniDepartment of Medicine, Cardiology Division, University Hospital Basel, Basel, Switzerland.
Tobias ReichlinDepartment of Cardiology, Inselspital, University Hospital Bern, Bern, Switzerland.
Nicolas RodondiInstitute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland.
Anne SpringerDepartment of Medicine, Cardiology Division, University Hospital Basel, Basel, Switzerland.
Annina StauberDepartment of Cardiology, Triemli Hospital Zurich, Zurich, Switzerland.
Christian SticherlingDepartment of Medicine, Cardiology Division, University Hospital Basel, Basel, Switzerland.
Thomas SzucsInstitute of Pharmaceutical Medicine (ECPM), University of Basel, Basel, Switzerland.
Stefan OsswaldDepartment of Medicine, Cardiology Division, University Hospital Basel, Basel, Switzerland.
Matthias SchwenkglenksEpidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland.
Swiss-AF Investigators

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsAtrial fibrillation (AF) costs are expected to be substantial, but cost comparisons with the general population are scarce. Using data from the prospective Swiss-AF cohort study and population-based controls, we estimated the impact of AF on direct healthcare costs from the Swiss statutory health insurance perspective.

methodsSwiss-AF patients, enrolled from 2014 to 2017, had documented, prevalent AF. We analysed 5 years of follow-up, where clinical data, and health insurance claims in 42% of the patients were collected on a yearly basis. Controls from a health insurance claims database were matched for demographics and region. The cost impact of AF was estimated using five different methods: (1) ordinary least square regression (OLS), (2) OLS-based two-part modelling, (3) generalised linear model-based two-part modelling, (4) 1:1 nearest neighbour propensity score matching and (5) a cost adjudication algorithm using Swiss-AF data non-comparatively and considering clinical data. Cost of illness at the Swiss national level was modelled using obtained cost estimates, prevalence from the Global Burden of Disease Project, and Swiss population data.

resultsThe 1024 Swiss-AF patients with available claims data were compared with 16 556 controls without known AF. AF patients accrued CHF5600 (EUR5091) of AF-related direct healthcare costs per year, in addition to non-AF-related healthcare costs of CHF11100 (EUR10 091) per year accrued by AF patients and controls. All five methods yielded comparable results. AF-related costs at the national level were estimated to amount to 1% of Swiss healthcare expenditure.

conclusionsWe robustly found direct medical costs of AF patients were 50% higher than those of population-based controls. Such information on the incremental cost burden of AF may support healthcare capacity planning.

Indexed as

Atrial FibrillationAlgorithmsCohort StudiesHealth Care CostsHumansProspective Studiescardiac epidemiologycardiologyhealth economics

Identifiers

PMID37709325
PMCPMC10503354

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.